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ABSTRACT
Objective Identify whether participants with lower 
education are less likely to report taking statins for 
primary cardiovascular prevention than those with higher 
education, but an equivalent increase in underlying 
cardiovascular risk.
Methods Using data from a large prospective 
cohort study, UK Biobank, we calculated a QRISK3 
cardiovascular risk score for 472 097 eligible participants 
with complete data on self- reported educational 
attainment and statin use (55% female participants; 
mean age 56 years). We used logistic regression to 
explore the association between (i) QRISK3 score and 
(ii) educational attainment on self- reported statin use. 
We then stratified the association between QRISK3 score 
and statin use, by educational attainment to test for 
interactions.
Results There was evidence of an interaction between 
QRISK3 score and educational attainment. Per unit 
increase in QRISK3 score, more educated individuals 
were more likely to report taking statins. In women with 
≤7 years of schooling, a one unit increase in QRISK3 
score was associated with a 7% higher odds of statin 
use (OR 1.07, 95% CI 1.07 to 1.07). In women with ≥20 
years of schooling, a one unit increase in QRISK3 score 
was associated with an 14% higher odds of statin use 
(OR 1.14, 95% CI 1.14 to 1.15). Comparable ORs in 
men were 1.04 (95% CI 1.04 to 1.05) for ≤7 years of 
schooling and 1.08 (95% CI 1.08, 1.08) for ≥20 years of 
schooling.
Conclusion Per unit increase in QRISK3 score, 
individuals with lower educational attainment were less 
likely to report using statins, likely contributing to health 
inequalities.
INTRODUCTION
Despite reductions in cardiovascular disease (CVD) 
morbidity and mortality in high- income countries, 
the most socioeconomically deprived groups have 
the highest risk of disease.1 There is evidence that 
education is a causal risk factor for CVD.2
Previous studies have assessed the association of 
socioeconomic position (SEP) with primary and 
secondary treatment rates for statins with mixed 
results.3–8 Lower education is associated with 
higher levels of cardiovascular risk factors2 and 
therefore a greater underlying cardiovascular risk 
and clinical need for statins. However, educational 
differences in health- seeking behaviours or inter-
actions between patients and clinicians, may mean 
patients with higher education are more likely to be 
prescribed statin medication.9 Independent of SEP, 
an overuse of statins in patients at low cardiovas-
cular risk and underuse of statins in patients at high 
cardiovascular risk has been reported.8 10
Using UK Biobank, we investigated whether 
for a unit increase in QRISK3 cardiovascular risk 
score,11 participants with lower education were less 
likely to report taking statins for primary preven-
tion than those with higher education. At the time 
of data collection (2006–2010), guidelines recom-
mended prescribing statins to individuals with a 
≥20% risk of experiencing an adverse cardiac event 
in 10 years, calculated using the Framingham risk 
score.12 In England and Wales, these guidelines 
have been updated to recommend prescribing 
based on a QRISK3 score of ≥10%.13 Cardiovas-
cular risk assessments are typically carried out by 
a primary healthcare professional during routine 
health checks. Since 2004, low- dose statins have 




At baseline, UK Biobank recruited 503 317 UK 
adults, aged 37–73 years, from 2006 to 2010. 
Participants attended assessment centres involving 
questionnaires, interviews, anthropometric and 
physical measurements.14 This analysis uses data 
from baseline assessments, linked hospital inpatient 
records and mortality statistics and linked primary 
care data (including prescriptions).
QRISK score
Cardiovascular risk was assessed using the publicly 
available QRISK3 algorithm (see https:// qrisk. org/ 
three/ index. php).11 QRISK3 scores were derived 
for all participants with complete data on educa-
tion, self- reported statin use and with no prev-
alent CVD (see exclusion criteria) (n=472 097) 
(figure 1). Multiple imputation was used for missing 
data in the QRISK3 variables (see ‘Statistical anal-
yses’ section).
See online supplemental methods and online 
supplemental table 1 for full details of all QRISK3 
variables and online supplemental tables 2 and 3 for 
UK Biobank treatment codes, International Classifi-
cation of Diseases (ICD)-9 and ICD-10 codes used 
to define diagnoses.
In a subset of individuals with linked primary 
care data, QRISK (read 2 code: 38DF.) (n=1495), 
and QRISK2 scores (read 2 code: 39DP.) (n=10 
 on A



















































































































































































































































































































2 Carter AR, et al. Heart 2021;0:1–7. doi:10.1136/heartjnl-2021-319238
Healthcare delivery, economics and global health
633) were recorded from 2007 onwards. In sensitivity analyses, 
the first recorded QRISK score was used.
Measuring education
Self- reported highest qualification was converted to the Interna-
tional Standard Classification for Education (ISCED) for years of 
education (online supplemental table 4).
Measuring statin use
Regularly prescribed medication was reported to study nurses, 
which was used define (i) statin use and (ii) type of statin 
used (atorvastatin, simvastatin, fluvastatin, pravastatin and 
rosuvastatin).
In individuals with primary care data, self- reported statin use 
was validated by a statin prescription both 3 months before and 
3 months after baseline. In sensitivity analyses using primary 
care QRISK scores, statin use was defined as any statin prescrip-
tion after a QRISK score was recorded, excluding individuals 
who reported using statins at baseline.
Exclusion criteria
Individuals were excluded if they had at least one diagnosis of 
myocardial infarction, angina, stroke, transient ischaemic attack, 
peripheral arterial disease, type 1 diabetes, chronic kidney disease 
or familial hypercholesterolaemia at baseline, as the National 
Institute for Health and Care Excellence guidelines state these 
diagnoses should result in a statin prescription,13 defined using 
ICD codes in hospital inpatient data (online supplemental table 
3).
Complete case analyses were carried out on 368 721 individ-
uals, with complete data on age, sex, education, self- reported 
statin use and all QRISK3 variables (online supplemental table 
1 and figure 1).
Code and data availability
The derived variables have been returned to UK Biobank. The 
code used to derive QRISK3 scores, and conduct analyses is 
available at  github. com/ alicerosecarter/ statin_ inequalities. All 
analyses were carried out in Stata V.16.1 (StataCorp, College 
Station, Texas, USA).
Statistical analyses
To maximise power and potentially reduce bias, multivari-
able multiple imputation by chained equations15 was used to 
impute missing data in QRISK3 variables, assuming missing at 
random. The imputation sample was defined as all individuals 
with complete data on education and reported statin use. The 
proportion of missing data  for  each  variable  ranged  from 0% 
to 15% (online  supplemental  table 5).  Imputation was  carried 
out within strata of education and sex to preserve interactions.16 
A total of 25 imputed datasets were generated,17 each analysed 
individually with results combined according to Rubin’s rules.
Because the QRISK3 score is derived sex- stratified, analyses 
were carried out sex- stratified.11
To confirm the validity of the derived QRISK3 score, a univari-
able logistic regression model was used to assess the association 
between QRISK3 score and (i) statin use (as defined previously) 
and (ii) incident CVD (see online supplemental methods).
We estimated the association between years of education with 
(i) QRISK3 score (using linear regression) and (ii) statin use 
(using logistic regression).
Testing for interaction between QRISK3 score and education on 
statin use
Logistic regression was used to estimate the association of 
QRISK3 score with statin use, stratified by years of education, 
estimating multiplicative interactions (online supplemental 
Figure 1 Study flow chart identifying eligible participants for analysis. BMI, body mass index; CVD, cardiovascular disease.
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figure 2, route 1). Analyses were adjusted for date of assessment 
to account for changes in statin prescribing guidelines during 
the recruitment period. No other covariates were adjusted 
for, assuming all relevant variables were incorporated into the 
QRISK3 score. Evidence of an interaction between QRISK3 
score and years of education was evaluated in a linear model 
where the interaction term QRISK3×education was included.
Secondary analyses
Atorvastatin has greater efficacy than simvastatin but is more 
costly.18 To test whether educational inequalities are present in 
the statin type prescribed, we estimated the interaction between 
QRISK3×education with atorvastatin compared with simvas-
tatin in statin users (online supplemental figure 1, route 2).
Analyses between QRISK3×education on statin use and type 
of statin were replicated using complete case data (online supple-
mental figure 1, routes 3 and 4).
Analyses were replicated in participants with linked primary 
care data using (i) baseline measures of QRISK3 and self- 
reported statin use (online supplemental figure 1, route 5), (ii) 
baseline measures of QRISK3 with validated statin use (online 
supplemental figure 1, route 6) and (iii) QRISK or QRISK2 score 
recorded in primary care data with statin prescriptions (online 
supplemental figure 1, route 7). Primary care QRISK scores 
were included if they were recorded on or prior to the date of 
first statin prescription, but time between both events was not 
accounted for.
Sensitivity analyses were carried out excluding participants 
who reported taking non- statin lipid- lowering therapies. Main 
analyses were also replicated on the additive scale for interaction.
Two further QRISK3 scores were derived using baseline data 
excluding (i) systolic blood pressure variability and (ii) family 
history of CVD from QRISK3 scores (see online supplemental 
methods). The pairwise correlation between scores with and 
without these variables was tested.
RESULTS
UK Biobank sample
In  primary  analyses  (n=472 097),  55%  of  participants  were 
female with a mean age of 56 years. In female participants, the 
QRISK3 score implied a mean 10- year risk of a cardiovascular 
event of 6.9% (SD=5.5). In male participants, the QRISK3 score 
implied mean a 10- year risk of a cardiovascular event of 13.1% 
(SD=8.4). Participants were more likely to have completed 
≥20  years  of  education  (female=35%,  male=38%)  than  ≤7 
years of education (female=14%, male=14%); 10% of female 
participants and 17% of male participantss reported using statins 
(online supplemental table 6).
The distribution of variables was similar between the multiply 
imputed data, complete case data and the subset of participants 
with primary care data (online supplemental table 6).
Association of QRISK3 score with statins and cardiovascular 
disease
Per one unit increase in QRISK3 score (ie, a 1% increase in the 
10- year risk of experiencing a cardiovascular event) in female 
participants,  the OR for statin use was 1.12 (95% CI 1.12 to 
1.13)  and  the OR  for  incident CVD was  1.14  (95% CI  1.14 
to 1.15) (figure 2, online supplemental figure 2 and online 
supplemental table 7). Female participants with a QRISK3 score 
of ≥10 were 1.34 times (95% CI 1.31 to 1.36) more likely to 
report using statins than those with a QRISK score <10. In male 
participants,  the OR for statin use was 1.07 (95% CI 1.07 to 
1.07)  and 1.09  (95% CI 1.09  to 1.09)  for  incident CVD per 
unit higher QRISK3 score (figure 2, online supplemental figure 
2 and online supplemental table 7). Male participants with a 
QRISK3 score of ≥10 were 1.49 times (95% CI 1.46 to 1.52) 
more likely to report using statins than those with a QRISK 
score <10. Participants reporting using statins had lower mean 
low- density lipoprotein cholesterol levels (the biological target 
Figure 2 OR for self- reported statin use per unit increase in baseline QRISK3 score with no education interaction and stratified by years of 
education in female and male participants, adjusted for date of baseline assessment centre. Analyses stratified by years of education provide an 
estimate of interaction on the multiplicative scale. P value for interaction in female participants=1.896×10−85 and male participants=1.999×10−48.
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of statins), compared with non- statin users (online supplemental 
figure 3).




in male participants (online supplemental table 8 and online 
supplemental figure 4).
Statin prevalence was highest in those with ≤7 years of educa-
tion (equivalent to no formal qualifications) across all strata of 
cardiovascular risk (online supplemental figure 5 and online 
supplemental table 9). Each additional year of education was 
associated with a lower odds of statin use (OR in female partici-
pants: 0.93; 95% CI 0.93 to 0.93; OR in male participant: 0.96; 
95% CI 0.96 to 0.96) (online supplemental figure 6).
Interaction between education and QRISK3 score in relation 
to statin use
There was evidence of an interaction between QRISK3×edu-
cation on statin use. In female participants, per unit increase in 
QRISK3, the OR for reporting statin use in those with ≥20 years 
(equivalent  to  obtaining  a  degree) was  1.14  (95% CI  1.14  to 
1.15) compared with an OR of 1.07 (95% CI 1.07 to 1.07) for 
those with ≤7 years of education (figure 1). In male participants, 





There was little evidence of an interaction between QRISK3×ed-
ucation on statin type (online supplemental table 10 and online 
supplemental figure 7).
In analyses in participants with primary care data using (i) 
baseline measures of QRISK3 and self- reported statin use, (ii) 
baseline measures of QRISK3 with prescription- validated statin 
use and (iii) QRISK or QRISK2 score recorded in primary 
care data with a statin prescription, similar interactions were 
observed to the main results, although evidence of an interaction 
was weaker in the primary care QRISK analyses in male partici-
pants (figure 3 and online supplemental figure 8).
Sensitivity analyses (i) using complete case data and (ii) 
excluding participants on non- statin- lowering therapy were 
consistent with the main results (online supplemental tables 11 
and 12). There was evidence of an additive interaction between 
Figure 3 OR for statin use recorded in primary care prescription data per unit increase in (A) baseline QRISK3 score and (B) QRISK or QRISK2 score 
recorded in primary care, in female and male participants adjusted for date of baseline assessment centre or date of QRISK assessment in primary 
care. Analyses stratified by years of education provide an estimate of interaction on the multiplicative scale. Baseline QRISK3: p value for interaction 
in female participants=5.476×10−10 and male participants=4.046×10−7 QRISK score recorded in primary care: p value for interaction in female 
participants=0.006 and male participants=0.413.
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QRISK3×education, although the strength of the interaction 
was weaker compared with the multiplicative scale (online 
supplemental figure 9).
Pairwise correlation between the baseline- derived QRISK3 
score and QRISK3 scores derived excluding (i) systolic blood 
pressure variability estimated from the difference between two 
baseline measures and (ii) self- report of any CVD in a mother, 
father or sibling, were high (all >0.97) (online supplemental 
table 13).
DISCUSSION
Despite a higher prevalence of statin use in less educated partic-
ipants, these participants were less likely to receive statin treat-
ment compared with more highly educated individuals given an 
equivalent increase in QRISK3 cardiovascular risk score.
Results in context
Cardiovascular risk factors partly mediate the association 
between education and CVD2 19–21 and likely contribute to 
the greater clinical need for statins in individuals with lower 
education. However, differences in cardiovascular preventative 
medication may be further contribute to socioeconomic inequal-
ities. We found the prevalence of statin use in participants at 
low  cardiovascular  risk  (QRISK3  score  of <10%) was  similar 
to previous analyses in UK primary care databases.10 However, 
notably here, we found the prevalence of statin use in partici-
pants with low cardiovascular risk (<10% QRISK3) was higher 
in participants with lower educational attainment compared 
with higher educational attainment.
Since 2009, National Health Service health checks have 
been offered to English and Welsh residents aged 40–74 years 
without pre- existing conditions every 5 years, aiming to prevent 
a number of diseases including CVD.22 A recent systematic 
review identified seven studies illustrating inequalities in favour 
of those with higher SEP attending preventative health checks,23 
including a  trend  towards  lower uptake  in  smokers;  a  socially 
patterned cardiovascular risk factor.23 24 Increased engagement 
with preventative screening may reduce inequalities in CVD 
and statins. However, in analyses using QRISK scores and statin 
prescriptions recorded in primary care data, these inequali-
ties remained. Therefore, health- seeking behaviours, including 
attending primary care clinics, cannot be the sole driver of 
inequalities.
Previous studies found mixed evidence for the association 
between SEP and statin use, including the direction of effect.3–8 
However, there was often limited consideration for underlying 
cardiovascular risk.3–6 Forde et al adjusted for Framingham 
risk score to control for cardiovascular risk.7 In contrast to our 
results, they found no evidence of inequalities in statin use by 
strata of employment grade in the Whitehall II study. This differ-
ence could be due to different measures of SEP (education vs 
employment) or cohort differences, where the Whitehall II study 
is an occupational cohort. The QRISK score has also been shown 
to have a greater predictive power than the Framingham risk 
score.25 Therefore, our analyses may better account for cardio-
vascular risk.
In participants with primary care data, a large number of 
participants reported taking statins to study nurses but had 
no prescription at baseline. These individuals are potentially a 
combination of those purchasing statins over the counter, having 
a private prescription or no longer being prescribed statins. 
Most individuals (91%) without a linked prescription reported 
taking simvastatin (the only statin available over the counter). It 
is possible that accessing statins through private practices or over 
the counter are further contributing to inequalities in cardiovas-
cular outcomes.
Strengths and limitations
The major strength of our work is the large sample size and 
array of data available. Given the age of participants, statin prev-
alence  is high. Using  linked primary care data  for 44% of  the 
eligible sample we could (i) validate self- reported statin use and 
(ii) compare different mechanisms inequalities may arise. Where 
inequalities are present in primary care QRISK scores, inequal-
ities are potentially due to factors within clinic settings. Using 
QRISK3 scores derived at baseline, inequalities may be due to 
differences in health- seeking behaviour.
Lifestyle and behavioural characteristics included in the 
QRISK3 score are likely measured more accurately in UK 
Biobank compared clinics. However, not all variables, or repeat 
measurements of variables specified in the QRISK3 algorithm 
are available in UK Biobank.11 The QRISK3 algorithm includes 
medications where an individual has two or more prescriptions 
for each class of medication (eg, corticosteroid or atypical anti-
psychotic). We relied on a single self- report measure at baseline, 
which may overestimate medication use. However, the magni-
tude to which these measurements differ is unlikely to introduce 
much bias to the QRISK3 score. Systolic blood pressure vari-
ability and coronary heart disease in a first- degree relative under 
the age of 60 years are not available in UK Biobank. Although we 
have included measures likely to capture some of these variables, 
this may introduce bias to the QRISK3 estimate.
Participants in UK Biobank are generally of a higher SEP and 
healthier than the general population, where higher education 
has been shown to increase participation and socially patterned 
cardiovascular risk factors including smoking decrease partici-
pation.14 26 Additionally, participants with lower SEP may differ 
from those of an equivalent SEP (or level of educational attain-
ment) in the general population. Therefore, inequalities in the 
wider population may be greater than those reported here.
In these data, it is not possible to identify who has both received 
a prescription and subsequently had the prescription filled, for 
example, in primary analyses, individuals with the lowest levels 
of educational attainment may have received a prescription for 
a statin, but not collected the medication. This may explain 
why the interaction between QRISK3 scores, and educational 
attainment is larger in the analyses using self- reported statin use 
compared with statin prescriptions in primary care data.
We have used the ISCED definitions of education as a measure 
of SEP. Although education is a strong predictor of adulthood 
SEP, correlating with future employment and income, adult 
SEP may explain some of the non- linearities observed in these 
results.27
Clinical implications
Our results indicate two potential mechanisms for these inequal-
ities. First, there are likely to be differences in health- seeking 
behaviour.28 Second, there are important interactions between 
the healthcare practitioner and patient resulting in unequal 
prescribing of statins.
Given persisting inequalities in CVD, addressing the contribu-
tion of inequalities in statin prescribing provides a clear policy 
target. However, this requires systemic change and different 
interventions may be required to address the different mecha-
nisms of inequalities. Future research should investigate what 
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factors are driving inequalities, such as patient preference for 
treatment29 or non- up- take of preventative health checks.
CONCLUSIONS
Our analyses demonstrate that for a unit increase in cardiovas-
cular risk, individuals with lower levels of education are less 
likely to be prescribed statins compared with individuals with 
higher education, meaning differences in statin prescribing likely 
contribute to inequalities in CVD. Policies should consider how 
these inequalities can be minimised.
Key messages
What is already known on this subject?
 ► Despite reductions in the rates of cardiovascular disease 
in high- income countries, individuals who are the most 
socioeconomically deprived remain at the highest risk of 
disease.
 ► Although intermediate lifestyle and behavioural risk factors 
explain some of this, much of the effect remains unexplained.
What might this study add?
 ► Per unit increase in QRISK3 score, a measure of clinical need, 
the likelihood of statin use increased more in individuals with 
high educational attainment compared with individuals with 
lower educational attainment.
 ► These results were similar when using UK Biobank to derive 
QRISK3 scores and when using QRISK scores recorded in 
primary care records, and when using self- reported statin 
prescription data or prescription data from primary care 
records.
How might this impact on clinical practice?
 ► The mechanisms leading to these differences are unknown, 
but both health- seeking behaviours and clinical factors may 
contribute.
 ► Clinicians and policy makers should consider how they can 
improve uptake of preventative health checks to carry out 
cardiovascular risk assessments, while also considering 
whether any clinic- level factors could be addressed to 
improve the uptake of statins in patients with lower 
education.
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All UK Biobank participants are linked to mortality records, hospital episode statistics (HES) or Scottish morbidity 
and mortality records (referred to jointly throughout as hospital admissions data), with data available from 1997 in 
England, 1998 in Wales and 1981 in Scotland, with the most recent entry recorded in this analysis in May 2017. A 
subset of participants (approximately 230,000) have linked primary care and prescribing data. 
Variable definitions for use in QRISK3 scores 
Diagnoses of disease 
Diagnoses of disease including arthritis, diabetes (type I and type II), systemic lupus erythromatosus, atrial 
fibrillation, chronic kidney disease, migraine, HIV/AIDS, severe mental illness and erectile dysfunction were 
ascertained via linked hospital inpatients data or via linked medication data. All variables and assumptions made 
are available in Supplementary Tables 2-4. 
 
Treatments 
Use of drugs at baseline (antihypertensives, corticosteroids and atypical antipsychotics) were defined by self-
reported medication use to clinic nurses at baseline. Individuals were coded as using medication if they reported 
any medication included in the QRISK3 score. In the QRISK3 derivation cohort individuals were required to have at 
least two prescriptions representing long term use. It was not possible to ascertain the number of prescriptions in 
UK Biobank; however, UK Biobank participants were asked to record regular treatments, rather than short term 
medication or over the counter medication. All treatment codes used to define these variables in UK Biobank are 
available in Supplementary Table 2. 
 
Behavioral, lifestyle and biological factors 
Ethnicity 
Ethnicity was reported by participants to study nurses at UK baseline assessment centres. Ethnicity was 
categorised according to the categories used in the QRISK3 algorithm. 
Townsend deprivation index 
Townsend deprivation index of current location was recorded by UK Biobank at baseline . 
BMI 
Height (m) and weight (kg) were measured by UK Biobank study nurses ate baseline assessment centres which 
were used to calculate BMI (kg/m2). 
Smoking 
Smoking status (never, former or current) was determined by self-reported data at baseline assessment centres. 
The number of cigarettes smoked per day in current smokers was reported at baseline assessment centres and 
categorised according to QRISK3 categories of light (1-9/day), moderate (10-19/day) and heavy smokers (≥20/day). 
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Biological factors 
Systolic blood pressure 
The mean from two resting automated measures of systolic blood pressure, measured using an Omron HEM-
7105IT digital blood pressure monitor, was used in the QRISK3 score. 
Systolic blood pressure variability 
In the absence of repeated measures of systolic blood pressure on UK biobank a measure of systolic blood 
pressure variability was derived from the standard deviation of the two recorded measurements of systolic blood 
pressure at the baseline assessment centre. 
Total cholesterol:HDL cholesterol ratio 
Non-fasting measures of total serum cholesterol and high-density lipoprotein (HDL)-cholesterol were measured 
using enzymatic assays (Backman Coulter AU5800) and the ratio of the two values was calculated. UK Biobank 
corrected serum data for laboratory dilution effects and were excluded if they did not pass UK Biobank quality 
control.  
Coronary heart disease in a first degree relative under 60 years of age 
A measure of family history of cardiovascular disease was ascertained from reported heart disease in mothers, 
fathers and siblings of UK Biobank participants, however age of diagnosis, nor type of cardiovascular disease, could 
not be determined. 
Incident cardiovascular disease 
The validity of QRISK3 scores was assessed by evaluating the association between QRISK3 and incident 
cardiovascular disease (CVD) (see statistical analyses in main text). Incident CVD was defined using hospital 
admissions data. All cardiovascular subtypes were combined to define cases, and cases were any individual with an 
ICD10 I code or G45, or an ICD9 code between 3900-4599 recorded (see sTable 3). The follow up period was 
defined as any event following date of baseline assessment centre (between 2006 and 2010) until the most recent 
date available in the linked hospital inpatient data (May 2017). 
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Additional Tables 
Supplementary Table 1: Variables used, and assumptions made, when generating 
QRISK3 scores in UK Biobank participants at baseline 
Variable included in 
QRISK3 algorithm 
Measured in UK 
Biobank by 
ICD Code UKBB Variable  Assumptions/limitations to the UK Biobank 
variables 
Diagnoses  
Arthritis Hospital inpatient data M05   
Diabetes (Type I and II) Hospital inpatient data  E10-E14   
Systemic lupus 
erythematosus 
Hospital inpatient data  M32.9   
Atrial fibrillation Hospital inpatient data  I48   
Chronic kidney disease  Hospital inpatient data  N18.3-N18.5   
Migraine Hospital inpatient data  G43   
HIV/AIDS Hospital inpatient data  B20   
Severe mental illness Hospital inpatient data  F20, F23, F31, 
F32, F33 
  
Erectile dysfunction Nurses interview 
treatment data 
N52  n_20003_0  
Treatments  
Antihypertensives Nurses interview 
treatment data 
 n_20003_0 Original QRISK3 derivation specifies that 
use of drugs at baseline was defined as at 
least two prescriptions, with the most 
recent one no more than 28 days before 
the date or cohort entry. This cannot be 
ascertained in UK Biobank baseline data  









Ethnicity Self-report  n_21000_0_0  
Townsend deprivation 
index 
Postcode at baseline  n_189_0_0  
BMI Baseline clinic  n_21001_0_0  
Smoking Self-report at baseline  n_20116_0_0 
n_3456_0_0 
Calculated from derived variable for 
cigarettes per day 
Biological Factors  
Age Baseline clinic  n_21003_0_0  
Systolic blood pressure Baseline clinic  n_4080_0_1 
n_4080_0_0 
 
Systolic blood pressure 
variability  
Baseline clinic  n_4080_0_1n_4080_
0_0 
The QRISK3 algorithm uses the standard 
deviation of repeated values of blood 
pressure. This was not available in UK 
Biobank; therefore, systolic blood pressure 
variability was derived from the standard 
deviation between two baseline 
automated readings of systolic blood 
pressure 
Total cholesterol: HDL 
ratio 





Coronary heart disease in 
first degree relative (<60 
years) 
Self-report  n_20107_0_0 
n_20110_0_0 
n_20111_0_0 
Includes all reported family history of CVD, 
not restricted to cases under 60 or specific 
subtypes 
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Supplementary Table 2: Treatment codes in UK Biobank to define medications 
Medication UK Biobank treatment code 
Statins 1141146234 1140888594 1140888648 1141192410 1140861958 
Erectile dysfunction 1140869100 1140883010 1141168936 1141168944 1141168946 1141168948 1141187810 
1141187814 1141187818 1141192248 1141192256 1141192258 1141192260 
Antihypertensives  1140860332 1140860334 1140860336 1140860338 1140860340 1140860342 1140860348 
1140860352 1140860356 1140860358 1140860362 1140860380 1140860382 1140860386 
1140860390 1140860394 1140860396 1140860398 1140860402 1140860404 1140860406 
1140860410 1140860418 1140860422 1140860426 1140860434 1140860454 1140860470 
1140860478 1140860492 1140860498 1140860520 1140860532 1140860534 1140860544 
1140860552 1140860558 1140860562 1140860564 1140860580 1140860590 1140860610 
1140860628 1140860632 1140860638 1140860654 1140860658 1140860690 1140860696 
1140860706 1140860714 1140860728 1140860736 1140860738 1140860750 1140860752 
1140860758 1140860764 1140860776 1140860784 1140860790 1140860802 1140860806 
1140860828 1140860830 1140860834 1140860836 1140860838 1140860840 1140860842 
1140860846 1140860848 1140860862 1140860878 1140860882 1140860892 1140860904 
1140860912 1140860918 1140860938 1140860942 1140860952 1140860954 1140860966 
1140860972 1140860976 1140860982 1140860988 1140860994 1140861000 1140861002 
1140861008 1140861010 1140861016 1140861022 1140861024 1140861034 1140861046 
1140861068 1140861070 1140861088 1140861090 1140861106 1140861110 1140861114 
1140861120 1140861128 1140861130 1140861136 1140861138 1140861166 1140861176 
1140861190 1140861194 1140861202 1140861266 1140861268 1140861276 1140861282 
1140861326 1140861384 1140864950 1140864952 1140866072 1140866074 1140866078 
1140866084 1140866086 1140866090 1140866092 1140866094 1140866096 1140866102 
1140866104 1140866108 1140866110 1140866116 1140866122 1140866128 1140866132 
1140866136 1140866138 1140866140 1140866144 1140866146 1140866156 1140866158 
1140866162 1140866164 1140866168 1140866182 1140866192 1140866194 1140866200 
1140866202 1140866206 1140866210 1140866212 1140866220 1140866222 1140866226 
1140866230 1140866232 1140866236 1140866244 1140866248 1140866262 1140866280 
1140866282 1140866306 1140866308 1140866312 1140866318 1140866324 1140866328 
1140866330 1140866332 1140866334 1140866340 1140866352 1140866354 1140866356 
1140866360 1140866388 1140866390 1140866396 1140866400 1140866402 1140866404 
1140866406 1140866408 1140866410 1140866412 1140866416 1140866418 1140866420 
1140866422 1140866426 1140866438 1140866440 1140866442 1140866444 1140866446 
1140866448 1140866450 1140866460 1140866466 1140866484 1140866506 1140866546 
1140866554 1140866692 1140866704 1140866712 1140866724 1140866726 1140866738 
1140866756 1140866758 1140866764 1140866766 1140866778 1140866782 1140866784 
1140866798 1140866800 1140866802 1140866804 1140875808 1140879758 1140879760 
1140879762 1140879778 1140879782 1140879786 1140879794 1140879798 1140879802 
1140879806 1140879810 1140879818 1140879822 1140879824 1140879826 1140879830 
1140879834 1140879842 1140879854 1140879866 1140888510 1140888512 1140888552 
1140888556 1140888560 1140888578 1140888582 1140888586 1140888646 1140888686 
1140888760 1140888762 1140909368 1140911698 1140916356 1140916362 1140917428 
1140923572 1140923712 1140923718 1140926778 1140926780 1141145658 1141145660 
1141145668 1141151016 1141151018 1141151382 1141152600 1141152998 1141153006 
1141153026 1141153032 1141153328 1141156754 1141156808 1141156836 1141156846 
1141157252 1141157254 1141164148 1141164154 1141164276 1141164280 1141165470 
1141165476 1141166006 1141167822 1141167832 1141171152 1141171336 1141171344 
1141172682 1141172686 1141172698 1141173888 1141180592 1141180598 1141187788 
1141187790 1141190160 1141192064 1141193282 1141193346 1141194794 1141194800 
1141194804 1141194808 1141194810 1141201038 1141201040 
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Corticosteroids 1140853854 1140854694 1140854700 1140854784 1140854788 1140854816 1140854834 
1140854888 1140854916 1140854990 1140857672 1140857678 1140862572 1140868364 
1140868370 1140873620 1140874790 1140874792 1140874794 1140874810 1140874814 
1140874816 1140874822 1140874896 1140874930 1140874936 1140874940 1140874944 
1140874950 1140874954 1140874956 1140874976 1140874978 1140875668 1140875684 
1140876032 1140876036 1140876044 1140876046 1140876052 1140876058 1140876076 
1140876104 1140876456 1140878562 1140879922 1140879934 1140881938 1140882152 
1140882622 1140882624 1140882626 1140882630 1140882694 1140882708 1140882718 
1140882722 1140882724 1140882728 1140882730 1140882732 1140882740 1140882742 
1140882756 1140882758 1140882764 1140882766 1140882768 1140882774 1140882776 
1140882778 1140882780 1140882782 1140882794 1140882800 1140882806 1140882808 
1140882816 1140882818 1140882820 1140882822 1140882824 1140882826 1140882830 
1140882832 1140882836 1140882840 1140882842 1140882844 1140882846 1140882848 
1140882850 1140882852 1140882864 1140882888 1140882892 1140882894 1140882896 
1140882898 1140882902 1140882904 1140882906 1140882908 1140882910 1140882914 
1140882916 1140882918 1140882920 1140882926 1140882928 1140882932 1140882934 
1140882938 1140883022 1140883026 1140883028 1140883030 1140883034 1140883038 
1140883040 1140883044 1140883048 1140883052 1140883054 1140883056 1140883058 
1140883060 1140883062 1140883064 1140884636 1140884640 1140884642 1140884646 
1140884654 1140884660 1140884664 1140884672 1140884676 1140884696 1140884700 
1140884704 1140884716 1140888074 1140888092 1140888098 1140888124 1140888130 
1140888134 1140888142 1140888150 1140888166 1140888168 1140888172 1140888176 
1140888178 1140888184 1140888194 1140909786 1140909894 1140910424 1140910634 
1141151424 1141157294 1141157402 1141157418 1141162532 1141164086 1141167174 
1141169844 1141173346 1141174512 1141174520 1141174548 1141174552 1141179072 
1141179982 1141180342 1141181062 1141181554 1141181610 1141189464 1141191748 
1141194840 1141195232 1141195280 
Second generation 
atypical Psychotics 
1140867420 1140867432 1140867444 1140927956 1140927970 1140928916 1141152848 
1141152860 1141153490 1141167976 1141177762 1141195974 1141202024 
Non-statin lipid-lowering 
therapies 
1140865576 1140865576 1141157416 1140861924 1141157260 1140861926 1140861928 
1140861936 1140861944 1140861922 1140861942 1140861946 1140861954 1140862026 
1140862028 1141175908 1141168568 1141171548 1141201306 1140888590 1140861848 
1140851880 1140851882 1140861856 1141157262 1140861858 1140926582 1140861866 
1140861324 1140861868 1141188546 1140861876 1140861878 1140861884 1141181868 
1140861892 1141162544 1141172214 1141182910 1140865752 1141157494 1141145830 
1141192736 1141192740 
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Supplementary Table 3: ICD codes used to define incident and prevalent cases of 
cardiovascular disease 
 
Cardiovascular event ICD9 ICD10 
Incident cardiovascular disease (all 
subtypes combined) 
3900-4599 I* G45 
Myocardial infarction 4100-4109, 4120-4129 I21, I22 
Angina 4139 I20 
Stroke 43- 4389 I6, G45 
Transient ischaemic attack 4359 G45 
Peripheral arterial disease 4439 I73.9 
Type 1 diabetes 2500- 25011, 25013, 2504-25041, 
25043, 2505-25051, 25053, 2506-
25061, 25063, 2507-25071, 25073, 
2509-25091, 25093 
E10 
Chronic kidney disease 5383, 5384, 5385 N183, N184, N185 




Supplementary Table 4: International Standard for Classification of Education codes 
mapped to UK Biobank self-report highest qualification to estimate years of education 
 
Qualification (As reported in UK Biobank) ISCED Years of education 
College or University degree  5 20 
NVQ or HND or HNC or equivalent 5 19 
Other prof. qual. e.g.: nursing, teaching 4 15 
A levels/AS levels or equivalent 3 13 
O levels/GCSEs or equivalent  2 10 
CSEs or equivalent 2 10 
None of the above 1 7 
Prefer not to answer Excluded 
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QRISK 24% 22% 
   
Age 0% 0% 
   
BMI 0.5% 0.7% 


















   
Ethnicity 0.5% 0.7% 
   
Smoking 0% 0% 
   
Family history of 
CVD 
0% 0% 
   
Statin (reported) 0% 0% 
   
Statin type 0% 0% 
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Supplementary Table 6: Descriptive characteristics of UK Biobank participants in i) the full eligible (imputed) sample analysed ii) the 
eligible (imputed) sample who also have linked primary care data iii) participants with linked primary care data and a recorded QRISK 
score and iv) participants with complete data on QRISK3 variables 
 
Variable 
Imputed analysis sample  
Primary care analysis sample 
(imputed) 
Primary care analysis sample with 
recorded QRISK 
Complete case analysis sample  
(N = 472 097) (N = 209 451) (N = 12 128) (N = 368 721) 
Female Males Female Males Female Male Female  Male 
(N = 261 147) (N = 210 950) (N = 117 038) (N = 92 413) (N = 7 338) (N = 4 790) (N = 201 532) (N = 167 189) 
Continuous variables Mean (SD) 
QRISK* 
QRISK3 (baseline) 6.87 (5.54) 12.98 (8.34) 6.94 (5.57) 13.11 (8.35) 6.21 (4.68) 11.44 (7.1) 6.84 (5.5) 12.97 (8.32) 
QRISK3 excluding ‘non-
validated’ statin users 
NA NA 6.09 (4.98) 11.54 (7.82) NA NA NA NA 
Recoded value of QRISK 
in primary care 
NA NA NA NA 10.17 (6.94) 16.11 (9.2) NA NA 
Age   56.23 (7.98) 56.44 (8.2) 56.26 (7.94) 56.5 (8.15) 56.28 (7.98) 56.45 (8.2) 56.28 (7.98) 56.45 (8.2) 
BMI   27.02 (5.15) 27.75 (4.2) 27.14 (5.18) 27.86 (4.23) 26.96 (5.08) 27.74 (4.18) 26.96 (5.08) 27.74 (4.18) 
Systolic blood pressure   135.14 (19.18) 140.94 (17.35) 135.46 (19.17) 141.31 (17.39) 135.15 (19.15) 141 (17.31) 135.15 (19.15) 141 (17.31) 
Townsend deprivation index   -1.38 (3.2) -1.31 (3.12) -1.41 (2.95) -1.36 (3.05) -1.4 (2.99) -1.34 (3.09) -1.4 (2.99) -1.34 (3.09) 
Total cholesterol:HDL cholesterol   3.86 (1) 4.48 (1.15) 3.88 (1.01) 4.49 (1.15) 3.84 (1) 4.49 (1.15) 3.84 (1) 4.49 (1.15) 
Categorical variables Percent of Sample (SE) Frequency (%) 
Years of education 
≤7 years 14.21 (0.08) 13.83 (0.09) 15.29 (0.12) 14.67 (0.14) 1 034 (14) 601 (13) 32 785 (16) 26 874 (16) 
8-10 years 19.4 (0.09) 13.52 (0.09) 19.1 (0.13) 13.36 (0.13) 1 520 (21) 649 (14) 39 795 (20) 22 945 (14) 
11-13 years 6.06 (0.05) 5.27 (0.06) 5.81 (0.08) 5.05 (0.09) 436 (6) 285 (6) 11 729 (6) 8 449 (5) 
14-15 years 12.83 (0.07) 10.04 (0.08) 12.69 (0.11) 10.16 (0.12) 961 (13) 497 (10) 26 936 (13) 17 161 (10) 
16-19 years 12.88 (0.07) 19.67 (0.1) 13.13 (0.11) 20.17 (0.16) 911 (12) 944 (20) 25 653 (13) 32 940 (20) 
≥20 years 34.62 (0.11) 37.67 (0.12) 33.98 (0.16) 36.58 (0.19) 2 476 (34) 1 814 (38) 64 634 (32) 58 820 (35) 
Ethnicity 
White 94.96 (0.05) 94.7 (0.06) 95.75 (0.07) 95.33 (0.08) 7 026 (96) 4 600 (96) 190 903 (95) 158 386 (95) 
Indian 0.98 (0.02) 1.2 (0.03) 1.04 (0.03) 1.3 (0.04) 66 (1) 49 (1) 2 082 (1) 2 108 (1) 
Pakistani 0.23 (0.01) 0.42 (0.02) 26.52 (0.02) 0.46 (0.03) 21 (0) 11 (0) 462 (0) 717 (0) 
Other Asian 0.48 (0.02) 0.6 (0.02) 0.4 (0.02) 0.58 (0.03) 25 (0) 22 (0) 982 (0) 979 (1) 
Black Caribbean 10.73 (0.02) 0.81 (0.02) 0.77 (0.03) 0.64 (0.03) 55 (1) 18 (0) 2 464 (1) 1 408 (1) 
Black African 0.68 (0.02) 0.86 (0.02) 0.46 (0.02) 0.54 (0.03) 40 (1) 21 (0) 1 435 (1) 1 406 (1) 
Chinese 0.38 (0.01) 0.28 (0.01) 0.32 (0.02) 0.23 (0.02) 26 (0) 26 (0) 719 (0) 719 (0) 
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Other 1.22 (0.02) 1.12 (0.03) 1.01 (0.03) 0.92 (0.04) 70 (1) 70 (1) 2 485 (1) 2 485 (1) 
Smoking 
Never 60.54 (0.11) 52.29 (0.13) 60.79 (0.16) 52.33 (0.19) 4 388 (60) 2 536 (53) 120 335 (60) 83 129 (50) 
Former 30.39 (0.1) 35.02 (0.12) 30.05 (0.15) 35.16 (0.19) 2 346 (32) 1 715 (36) 63 059 (31) 63 033 (38) 
Light (1-9/day) 1.66 (0.03) 1.29 (0.03) 1.59 (0.04) 1.24 (0.04) 128 (2) 57 (1) 3 287 (2) 2 056 (1) 
Moderate (10-19/day) 2.99 (0.04) 2.96 (0.04) 3.16 (0.06) 3.01 (0.07) 176 (2) 102 (2) 6 094 (3) 4 931 (3) 
Heavy (>20/day) 4.42 (4.42) 8.45 (0.07) 4.42 (0.07) 8.26 (0.11) 300 (4) 380 (8) 8 757 (4) 14 040 (8) 
Type 2 diabetes 
Control 99.07 (0.02) 98.31 (0.03) 99.09 (0.03) 98.30 (0.04) 7 329 (00) 4 780 (100) 199 700 (99) 164 395 (98) 
Case 0.93 (0.02) 1.69 (0.03) 0.91 (0.03) 1.70 (0.04) 9 (0) 10 (0) 1 832 (1) 2 794 (2) 
Family history of CVD 
Control 72.37 (0.1) 78.22 (0.11) 71.5 (0.15) 77.57 (0.16) 5 242 (71) 3 749 (78) 142 641 (71) 128 314 (77) 
Case 27.63 (0.1) 21.78 (0.11) 28.5 (0.15) 22.43 (0.16) 2 096 (29) 1 041 (22) 58 891 (29) 38 875 (23) 
Cardiovascular risk (strata of 
QRISK score) 
Low cardiovascular risk 
(<10%) 
76.57 (0.09) 42.01 (0.01) 76.16 (0.13) 41.28 (0.17) 3 993 (54) 1 328 (28) 154 582 (77) 70 093 (42) 
Medium risk (≥10% - 
<20%) 
20.70 (0.08) 39.59 (0.11) 21.08 (0.13) 39.98 (0.17) 2 685 (37) 1 964 (41) 41 579 (21) 66 488 (40) 
High risk (≥20%) 2.73 (0.03) 18.39 (0.09) 2.76 (0.05) 18.75 (0.13) 660 (9) 1 498 (31) 5 371 (3) 30 608 (18) 
Statin (reported) 
Control 90.27 (0.06) 82.99 (0.08) 90.14 (0.09) 82.39 (0.13) NA NA 181 903 (90) 138 619 (83) 
Case 9.73 (0.06) 17.01 (0.08) 9.86 (0.09) 17.61 (0.13) NA NA 19 629 (10) 28 570 (17) 
Statin type 
No statin 90.27 (0.06) 82.99 (0.08) 90.14 (0.09) 82.39 (0.13) NA NA 181 903 (90) 138 619 (83) 
Atorvastatin 1.64 (0.02) 2.87 (0.04) 1.68 (0.04) 2.9 (0.06) NA NA 19 629 (10) 28 570 (17) 
Fluvastatin 0.02 (0) 0.06 (0.01) 0.03 (0) 0.06 (0.01) NA NA 181 903 (90) 138 619 (83) 
Pravastatin 0.3 (0.01) 0.47 (0.01) 0.29 (0.02) 0.44 (0.02) NA NA 3 281 (2) 4 750 (3) 
Rosuvastatin 0.39 (0.01) 0.61 (0.02) 0.38 (0.02) 0.65 (0.03) NA NA 49 (0) 96 (0) 
Simvastatin 7.37 (0.05) 13.01 (0.07) 7.49 (0.08) 13.56 (0.11) NA NA 617 (0) 787 (0) 
Statin (validated) 
Control NA NA 97.62 (0.05) 95.40 (0.08) 6 345 (86) 3 878 (81) NA NA 
Case NA NA 2.38 (0.05) 4.60 (0.08) 993 (14) 912 (19) NA NA 
Reported statin with no 
prescription* 
Control NA NA 92.90 (0.08) 86.01 (0.13) NA NA NA NA 
Case NA NA 7.10 (0.08) 13.99 (0.13) NA NA NA NA 
Non-statin lipid lowering therapy 
Control (including statin 
users) 
99.13 (0.02) 98.79 (0.02) 99.09 (0.03) 98.83 (0.04) 7 327 (100) 4 785 (100) 199 770 (99) 165 154 (99) 
Case 0.87 (0.02) 1.21 (0.02) 0.91 (0.03) 1.16 (0.04) 11 (0) 5 (0) 1762 (1) 2035 (1) 
Incident CVD 
Control 79.63 (0.08) 0.08 (73.66) 79.85 (0.13) 0.13 (73.57) 5 379 (82) 3 439 (80) 140 753 (79) 106 032 (74) 
Case 20.37 (0.08) 0.08 (26.34) 20.15 (0.13) 0.13 (26.43) 1 179 (18) 885 (20) 36 401 (21) 38 171 (26) 
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Derived QRISK3 variable from baseline measured in UK Biobank for the full analysis sample and primary care analysis sample, recorded QRISK or QRISK2 scores in primary care 
data for the primary care analysis sample with recorded QRISK. 
*Proportion of individuals excluding individuals with validated prescriptions 
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Supplementary Table 7: Odd ratio for i) statin use and ii) incident cardiovascular 
disease per unit increase in QRISK3 score and unit increase in years of education, 






Odds ratio (95% CI) 
(N = 201 532) 
Imputed sample 
Odds ratio (95% CI) 
(N = 261 147) 
Complete Case 
Odds ratio (95% CI) 
(N = 167 189) 
Imputed sample 
Odds ratio (95% CI) 
(N = 210 950) 
QRISK3 




1.143 (1.140, 1.146) 1.119 (1.116, 1.122) 1.088 (1.086, 1.090) 1.082 (1.080, 1.084) 
 
Education 




0.949 (0.946, 0.951) 0.949 (0.946, 0.951) 0.956 (0.954, 0.958) 0.948 (0.945, 0.951) 
 
Supplementary Table 8: Mean difference in QRISK3 score per unit increase in 





Mean difference (95% 
CI) 
(N = 201 532) 
Imputed Sample 
Mean difference (95% 
CI) 
(N = 261 147) 
Complete Case 
Mean difference (95% 
CI) 
(N = 167 189) 
Imputed Sample 
Mean difference (95% 
CI) 
(N = 210 950) 




BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Heart
 doi: 10.1136/heartjnl-2021-319238–7.:10 2021;Heart, et al. Carter AR
Supplementary Table 9: Percent of participants reporting statin use in low, medium and high cardiovascular risk groups, 
stratified by years of education and the association between education and statin use stratified by cardiovascular risk, 
adjusted by date of baseline assessment centre 
10-year 
cardiovascular risk 
Years of Education 










Odds ratio for 










Odds ratio for 
statin use (95% CI) 
Low risk <10 
All years  6.39 (0.06)   6.81 (0.09)  
≤7 years 11.46 (0.07) 12.24 (0.22) Reference 7.43 (0.09) 9.88 (0.04) Reference 
8-10 years 19.64 (0.09) 6.63 (0.13) 0.51 (0.48, 0.54) 14.88 (0.12) 6.22 (0.22) 0.60 (0.54, 0.68) 
11-13 years 6.21 (0.05) 5.52 (0.21) 0.42 (0.38, 0.46) 5.66 (0.08) 7.03 (0.37) 0.69 (0.60, 0.79) 
14-15 years 12.79 (0.08) 7.26 (0.16) 0.56 (0.53, 0.60) 8.76 (0.10) 8.05 (0.31) 0.80 (0.71, 0.90) 
16-19 years 13.91 (0.08) 5.62 (0.14) 0.43 (0.40, 0.46) 21.32 (0.14) 6.67 (0.19) 0.65 (0.59, 0.72) 
≥20 years 36.00 (0.10) 4.54 (0.01) 0.34 (0.32, 0.36) 41.95 (0.17) 6.26 (0.13) 0.61 (0.55, 0.67) 
 
 All years  19.60 (0.18)   22.40 (0.15)  
Medium risk (≥10 & 
<20) 
≤7 years 31.72 (0.21) 23.26 (0.33) Reference 19.18 (0.14) 26.58 (0.36) Reference 
8-10 years 19.03 (0.17) 19.26 (0.41) 0.79 (0.74, 0.84) 12.67 (0.12) 22.94 (0.42) 0.82 (0.78, 0.87) 
11-13 years 4.67 (0.09) 16.80 (0.77) 0.67 (0.60, 0.75) 4.84 (0.08) 21.25 (0.66) 0.75 (0.69, 0.81) 
14-15 years 14.46 (0.09) 18.69 (0.45) 0.76 (0.71, 0.81) 11.44 (0.11) 22.78 (0.43) 0.82 (0.77, 0.87) 
16-19 years 9.09 (0.13) 18.58 (0.56) 0.75 (0.69, 0.82) 18.59 (0.14) 21.69 (0.34) 0.76 (0.73, 0.81) 
≥20 years 21.02 (0.18) 16.08 (0.35) 0.63 (0.59, 0.67) 33.27 (0.17) 20.23 (0.25) 0.70 (0.67, 0.73) 
 
 All years  28.42 (0.56)   28.72 (0.24)  
High risk (≥20%) 
≤7 years 43.65 (0.61) 30.26 (0.86) Reference 30.78 (0.24) 31.35 (0.43) Reference 
8-10 years 16.21 (0.45) 28.61 (0.01) 0.92 (0.78, 1.07) 12.37 (0.17) 29.27 (0.67) 0.91 (0.84, 0.98) 
11-13 years 3.80 (0.23) 27.61 (2.78) 0.88 (0.66, 1.17) 4.20 (0.11) 25.64 (1.11) 0.76 (0.67, 0.85) 
14-15 years 12.69 (0.41) 28.61 (1.56) 0.92 (0.78, 1.09) 10.97 (0.16) 29.39 (0.71) 0.91 (0.84, 0.99) 
16-19 years 8.24 (0.34) 28.51 (1.96) 0.91 (0.74, 1.12) 17.22 (0.20) 28.17 (0.56) 0.91 (0.80, 0.92) 
≥20 years 15.42 (0.44) 23.03 (1.29) 0.69 (0.58, 0.81) 24.47 (0.22) 25.76 (0.47) 0.76 (0.71, 0.81) 
SE = standard error; CI = confidence interval
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Supplementary Table 10: Odds ratio for Atorvastatin (case) use compared with 
Simvastatin (control) use per unit increase in QRISK3 score and by strata of 






Odds ratio (95% CI) 
(N = 18 180) 
Imputed sample 
Odds ratio (95% CI) 
(N = 23 538) 
Complete Case 
Odds ratio (95% CI) 
(N = 26 633) 
Imputed sample 
Odds ratio (95% CI) 
(N = 33 499) 
QRISK3 1.023 (1.017, 1.029) 
1.0249 (1.020, 
1.030) 




All years 1.001 (0.997, 1.006) 0.994 (0.988, 1.001) 1.004 (0.998, 1.010) 1.001 (0.996, 1.006) 
≤7 years Baseline Baseline 
8-10 years 1.033 (0.93, 1.15) 0.992 (0.901, 1.091) 1.033 (0.926, 1.153) 0.990 (0.899, 1.090) 
11-13 years 1.16 (0.926, 1.394) 1.079 (0.919, 1.267) 0.992 (0.843, 1.167) 1.001 (0.868, 1.153) 
14-15 years 1.139 (1.011, 1.284) 1.071 (0.965 1.190) 1.003 (0.895, 1.124) 0.980 (0.886, 1.084) 
16-19 years 0.989 (0.863, 1.133) 0.930 (0.825, 1.048) 1.026 (0.930, 1.132) 0.990 (0.907, 1.079) 
≥20 years 0.940 (0.842, 1.049) 0.911 (0.829, 1.002) 1.070 (0.981, 1.167) 1.018 (0.943, 1.099) 
Note: Atorvastatin is generally regarded as more efficacious than Simvastatin. Simvastatin is available to purchase 
over the counter  
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Supplementary Table 11: Odd ratio for i) statin use and ii) Atorvastatin use (case) 
compared with Simvastatin (control) use per unit increase in QRISK3 score stratified 
by educational attainment in the complete case sample to test for evidence of a 







Odds ratio (95% CI) 
(N = 261 147) 
P Value for 
interaction 
Complete Case 
Odds ratio (95% CI) 
(N = 210 950) 




≤7 years 1.068 (1.064, 1.073) 
7.83x10-105 
1.042 (1.039, 1.045) 
7.40x10-66 
8-10 years 1.123 (1.117, 1.129) 1.078 (1.073, 1.082) 
11-13 years 1.131 (1.119, 1.144) 1.064 (1.057, 1.072) 
14-15 years 1.119 (1.112, 1.127) 1.061 (1.056, 1.066) 
16-19 years 1.140 (1.132, 1.149) 1.075 (1.071, 1.079) 
≥20 years 1.141 (1.135, 1.147) 1.079 (1.076, 1.082) 
  
Complete Case 
Odds ratio (95% CI) 
(N = 18 180) 
 
Complete Case 
Odds ratio (95% CI) 





≤7 years 1.021 (1.011, 1.031) 
0.733 
1.019 (1.012, 1.027) 
0.061 
8-10 years 1.029 (1.015, 1.042) 1.012 (1.002, 1.023) 
11-13 years 1.039 (1.014, 1.065) 1.015 (0.997, 1.033) 
14-15 years 1.023 (1.008, 1.039) 1.031 (1.019, 1.043) 
16-19 years 1.017 (0.988, 1.035) 1.023 (1.014, 1.032) 
≥20 years 1.024 (1.010, 1.038) 1.012 (1.005, 1.019) 
Analyses adjusted for date of baseline assessment centre 
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Supplementary Table 12: Odds ratio for statin use per unit increase in QRISK3 score 
stratified by educational attainment in the complete case sample to test for evidence 






Odds ratio using 
imputed data  (95% 
CI) 
(N = 258 863) 
P Value for 
interaction 
Odds ratio using 
imputed data (95% 
CI) 
(N = 208 400) 




≤7 years 1.071 (1.067, 1.077) 
117x10-82 
1.044 (1.041, 1.047) 
5.15x10-46 
8-10 years 1.126 (1.121, 1.132) 1.078 (1.074, 1.082) 
11-13 years 1.134 (1.123, 1.145) 1.068 (1.062, 1.075) 
14-15 years 1.120 (1.114, 1.127) 1.065 (1.061, 1.070) 
16-19 years 1.143 (1.135, 1.151) 1.077 (1.073, 1.080) 
≥20 years 1.145 (1.139, 1.150) 1.081 (1.078, 1.084) 
 
Odds ratio using 
complete case data 
(95% CI) 
(N = 199 770) 
P Value for 
interaction 
Odds ratio using 
complete case data 
(95% CI) 
(N = 165 154) 




≤7 years 1.070 (1.065, 1.075) 
5.17x10-26 
1.043 (1.040, 1.046) 
1.04x10-16 
8-10 years 1.125 (1.119, 1.132) 1.079 (1.073, 1.082) 
11-13 years 1.131 (1.118, 1.143) 1.065 (1.057, 1.072) 
14-15 years 1.121 (1.113, 1.128) 1.063 (1.058, 1.068) 
16-19 years 1.144 (1.136, 1.153) 1.076 (1.072, 1.080) 
≥20 years 1.143 (1.137, 1.149) 1.080 (1.076, 1.083) 
 
Analyses adjusted for date of baseline assessment centre 
In the imputation sample 2 284 females and 2 550 males were excluded for use of non-statin lipid lowering 
therapies.  
In the complete-case sample, 1 726 females and 2035 males were excluded for use of non-statin lipid lowering 
therapies. 
 
Supplementary Table 13: Pairwise correlation for QRISK3 scores derived from baseline 
measures in UK Biobank including all variables and excluding i) family history of CVD 
and iii) systolic blood pressure variability 
 
QRISK3 score Pairwise correlation with complete score 
Female 
Excluding reported family history of any cardiovascular 
disease at any age 
0.9799 
Excluding systolic blood pressure from two baseline 
measures of systolic blood pressure 
0.9991 
Male 
Excluding reported family history of any cardiovascular 
disease at any age 
0.9736 
Excluding systolic blood pressure from two baseline 
measures of systolic blood pressure 
0.9984 
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Supplementary Figure 6: Odds ratio for statin use per year unit increase in educational 
attainment (all years) and per strata of educational attainment 
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Supplementary Figure 7: Odds ratio for Atorvastatin prescribing (case) compared to 
Simvastatin (control), per unit increase in QRISK3 score with no education 
interaction and stratified by years of education in females and males to test for 
evidence of an interaction 
 
Analyses adjusted for date of baseline assessment centre 


















20 years or more
16 - 19 years
14 - 15 years
11 - 13 years
8 - 10 years
7 years or less
No education interaction
20 years or more
16 - 19 years
14 - 15 years
11 - 13 years
8 - 10 years

















































0.98 1.00 1.02 1.04 1.06
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Heart
 doi: 10.1136/heartjnl-2021-319238–7.:10 2021;Heart, et al. Carter AR
Supplementary Figure 8: Odds ratio for self-report statin use per unit increase in 
baseline QRISK3 score with no education interaction and stratified by years of 
education to test for evidence of an interaction in the subsample of females and 
males with linked primary care data 
 
Analyses adjusted for date of baseline assessment centre 
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Supplementary Figure 9 : Risk difference for self-report statin use per unit increase 
in baseline QRISK3 score with no education interaction and stratified by years of 
education in females and males to test for an interaction on the additive scale 
 
Analyses adjusted for date of baseline assessment centre 
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